Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer

Francesca V. Negri, Pellegrino Crafa, Giuseppe Pedrazzi, Cecilia Bozzetti, Costanza Lagrasta, Giorgio Gardini, Ione Tamagnini, Alessandra Bisagni, Cinzia Azzoni, Lorena Bottarelli, Gallia Graiani, Ida Romano, Rosa Porzio, Gian P. Bacchini, Carlo Paties, Gianluca Tomasello, Giovanni Marchetti, Silvia Fanello, Carmine Pinto, Roberto SalaAndrea Ardizzoni

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To assess the role of Notch activation in predicting bevacizumab efficacy in colorectal cancer (CRC). Materials & methods: Notch activation was evaluated by immunohistochemistry (IHC) on 65 CRC enrolled within randomized clinical trials assessing first-line bevacizumab-based chemotherapy and on 21 CRC treated with chemotherapy alone. Results: Strong Notch (IHC 3+) activation was negatively associated with response (18 vs 62% in low Notch cases [IHC 0, 1, 2+]; p = 0.016), progression-free survival (4.9 vs 12.1 months; p = 0.002) and overall survival (19.3 vs 30.4 months; p = 0.039). No correlation was found between Notch activation and clinical outcome in CRC treated with chemotherapy alone. Conclusion: A potential role of Notch activation in the antitumor activity of bevacizumab could be hypothesized.

Original languageEnglish
Pages (from-to)3167-3174
Number of pages8
JournalFuture Oncology
Volume11
Issue number23
DOIs
Publication statusPublished - 2015

Keywords

  • bevacizumab
  • colorectal cancer
  • DLL4
  • Notch activation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this